Shares of Inflarx NV (NASDAQ:IFRX) have been given a consensus rating of “Buy” by the ten brokerages that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $55.00.
IFRX has been the topic of a number of research reports. Zacks Investment Research downgraded Inflarx from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Robert W. Baird initiated coverage on Inflarx in a research note on Monday, January 28th. They issued an “outperform” rating and a $62.00 price objective on the stock.
Shares of IFRX opened at $42.51 on Friday. The company has a market cap of $1.10 billion, a P/E ratio of -30.36 and a beta of -0.63. Inflarx has a 12-month low of $20.31 and a 12-month high of $53.10.
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Inflarx by 137.4% in the 3rd quarter. Vanguard Group Inc. now owns 162,460 shares of the company’s stock worth $5,576,000 after acquiring an additional 94,020 shares during the last quarter. Paloma Partners Management Co bought a new position in shares of Inflarx during the 4th quarter valued at approximately $526,000. Essex Investment Management Co. LLC bought a new position in shares of Inflarx during the 4th quarter valued at approximately $798,000. JPMorgan Chase & Co. increased its position in shares of Inflarx by 29.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after purchasing an additional 2,420 shares during the last quarter. Finally, RA Capital Management LLC increased its position in shares of Inflarx by 6.0% during the 4th quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock valued at $75,835,000 after purchasing an additional 117,241 shares during the last quarter. 51.01% of the stock is currently owned by institutional investors and hedge funds.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Story: Quiet Period Expirations
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.